SLG
ALDX icon

Stanley-Laman Group’s Aldeyra Therapeutics ALDX Stock Holding History

Stanley-Laman Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-98,892
Closed -$786K – 221
2018
Q2 		$786K Buy
98,892
+34,863
+54% +$278K 0.18% 172
2018
Q1 		$480K Buy
+64,029
New +$486K 0.11% 220

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Stanley-Laman Group's ALDX Position: Q3 2018 in Review

Stanley-Laman Group sold out of Aldeyra Therapeutics (ALDX) in Q3 2018, closing a stake of 98,892 shares — an estimated $786K sold.

Stanley-Laman Group first reported a position in ALDX in Q1 2018 and held it in 2 quarters. The position peaked at $786K in Q2 2018. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2018.

  • Stanley-Laman Group reported no remaining Aldeyra Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 98,892 Aldeyra Therapeutics shares in Q3 2018, an estimated $786K.
  • Stanley-Laman Group first reported a position in Aldeyra Therapeutics in Q1 2018 and held it in 2 quarters.
  • Stanley-Laman Group's Aldeyra Therapeutics position peaked at $786K in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.